Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, has been reported to inhibit endocytosis and intracellular trafficking of multiple viruses, including hepatitis C, dengue, and Ebola, exerting broad-spectrum antiviral effects by increasing ACE2 expression (44). Here, EGFR is linked to dengue disease.